NXP900 + Osimertinib

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Mutation Positive Non-small Cell Lung Cancer

Conditions

EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

Trial Timeline

Dec 18, 2025 → Jun 1, 2027

NCT ID

NCT07315113

About NXP900 + Osimertinib

NXP900 + Osimertinib is a phase 1 stage product being developed by Nuvectis Pharma for EGFR Mutation Positive Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07315113. Target conditions include EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients.

What happened to similar drugs?

1 of 7 similar drugs in EGFR Mutation Positive Non-small Cell Lung Cancer were approved

Approved (1) Terminated (1) Active (5)

🔄AZD9291 + MEDI4736AstraZenecaPhase 3

🔄AZD9291 80mg oral each dayAstraZenecaPhase 3

✅GefitinibAstraZenecaApproved

🔄AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mgAstraZenecaPhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

❌ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLYRochePhase 3

🔄Dacomitinib (PF-00299804) + GefitinibPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07315113	Phase 1	Recruiting	Dec 18, 2025	Jun 1, 2027	EGFR Mutation Positive Non-small Cell Lung Cancer

Competing Products

20 competing products in EGFR Mutation Positive Non-small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	32
YH32364	Yuhan	Phase 1/2	39
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
ASP8273	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
erlotinib	Astellas Pharma	Phase 1	29
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	27
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	31
ABT-414	AbbVie	Pre-clinical	26
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	29
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
AZD9291 + MEDI4736	AstraZeneca	Phase 3	40
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	22
AZD9291	AstraZeneca	Pre-clinical	26
Osimertinib	AstraZeneca	Phase 2	35
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	24
AZD9291 80mg oral each day	AstraZeneca	Phase 3	36
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	31
Osimertinib	AstraZeneca	Phase 2	35